Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an announcement.
Shanghai Haohai Biological Technology Co., Ltd. has established a remuneration and appraisal committee under its Board of Directors to enhance its remuneration management system. This committee is responsible for setting performance evaluation indicators and remuneration systems for directors and senior management, ensuring a formal and transparent process for developing remuneration policies, and making recommendations on remuneration packages. The move aims to align the company’s governance with regulatory requirements and improve oversight of executive compensation, potentially impacting its market positioning and stakeholder confidence.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and provision of biological products and services. The company is listed on both the Science and Technology Innovation Board of the Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited.
Average Trading Volume: 698,022
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.93B
Learn more about 6826 stock on TipRanks’ Stock Analysis page.